Clinical trials: Placebo - Control
Parkinson Disease
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a diagnosis of Parkinson's Disease consistent with the UK Parkinson's Disease Society (UKPDS) Brain Bank…
- Trial name
- NCT05766813
- Testing
- Lenrispodun
- Where
- 35 sites in United States
- Volunteers
- 79 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia
A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase
A clinical study to investigate the effect of 2 doses of an investigational drug in acutely psychotic adult patients with schizophrenia. The study will consist of a double-blind phase followed by an open-label extension phase.
- Trial name
- NCT04825860
- Testing
- SEP-363856 50 mg, SEP-363856 75 mg
- Where
- 54 sites in China, Japan and 2 more
- Volunteers
- 83 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Attention Deficit Disorder With Hyperactivity
A Study of the Effectiveness and Safety of Prolonged-release Methylphenidate Hydrochloride in Adult Patients With Attention Deficit/Hyperactivity Disorder.
The purpose of this study is to evaluate the effectiveness and safety of three doses of prolonged-release methylphenidate (a central nervous system (CNS) stimulant) in adult patients with attention deficit/hyperactivity disorder…
- Trial name
- NCT00246220
- Testing
- methylphenidate hydrochloride
- Volunteers
- 402 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Alzheimer Disease
Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects
A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects with Mild-to-Moderate Alzheimer's Disease.
- Trial name
- NCT04251182
- Testing
- 15mg T3D-959, 30 mg T3D-959, 45 mg T3D-959
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- T3D Therapeutics, Inc.
Dementia, Alzheimer Disease
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With Dementia
The purpose of the study is to evaluate the safety and efficacy of risperidone (an antipsychotic medication) versus placebo in the treatment of behavioral disturbances associated with dementia.
- Conditions
- Dementia, Alzheimer Disease, Dementia, Vascular
- Trial name
- NCT00253123
- Testing
- risperidone
- Volunteers
- 626 people
- Sponsor
- Janssen, LP
Influenza
Post-marketing Study to Evaluate the Efficacy of Influenza Vaccine
As a result of the recent supply shortages in the U.S., as well as an anticipated increase in demand during the coming years, GSK Biologicals is pursuing licensure of Fluarix in the U.S.
- Trial name
- NCT00197223
- Testing
- Influenza vaccine
- Where
- Czechia
- Volunteers
- 6,213 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Charcot-Marie-Tooth Disease
Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease
This is a multicenter, phase 2 study to evaluate the safety, tolerability, pharmacodynamics (PD), efficacy, and pharmacokinetics (PK) of ACE-083 in patients with Charcot-Marie-Tooth Disease Type 1 and Type X (CMT1 and CMTX), to…
- Trial name
- NCT03124459
- Testing
- ACE-083
- Where
- 16 sites in United States
- Volunteers
- 63 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Obesity, Overweight
A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects
The purpose of this study is to determine whether 2 doses of the combination of naltrexone SR and bupropion SR are safe and effective in the treatment of obesity.
- Trial name
- NCT00532779
- Testing
- Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Naltrexone SR 32 mg/Bupropion SR 360 mg /day, Ancillary therapy
- Where
- 34 sites in United States
- Volunteers
- 1,742 people
- Sponsor
- Orexigen Therapeutics, Inc
Hepatitis B, Chronic
Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy
The study is a phase 2a, single blind, randomized, placebo controlled, study evaluating the safety, anti-viral activity, and pharmacokinetics (PK) following multiple doses of intravenous ARB-001467
- Trial name
- NCT02631096
- Testing
- ARB-001467
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 36 people
- Sponsor
- Arbutus Biopharma Corporation
Ulcerative Colitis
Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis
SPH3127-US-01 is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics, and preliminary efficacy of SPH3127 for the treatment of mild-to-moderate ulcerative colitis.
- Trial name
- NCT05019742
- Testing
- SPH3127
- Where
- 16 sites in United States
- Volunteers
- 3 people
- Sponsor
- Shanghai Pharma Biotherapeutics USA Inc.
Chronic Constipation
Study to Evaluate the Effects of RM-131 in Patients With Chronic Constipation
The purpose of this study is to evaluate safety and tolerability as well as the effects of RM-131 on colonic motor and sensory effects in patients with chronic constipation.
- Trial name
- NCT02137642
- Testing
- RM-131
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Motus Therapeutics, Inc.
Diabetes Mellitus, Type 2
A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart
Part A: The purpose of Part A of the study is to look at the electrocardiogram (ECG) effects due to blood sugar changes after a meal compared to when LY2409021 is also given with a meal.
- Trial name
- NCT01460368
- Testing
- LY2409021, Moxifloxacin
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obstetric Labour, Premature
The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor
Pre-Term Labor (prior to 37 weeks gestation) is the largest single cause of infant morbidity and mortality and is frequently associated with long-term disability. Oxytocin is a hormone produced by the body during labor.
- Trial name
- NCT00404768
- Testing
- GSK221149A
- Where
- 57 sites in United States, Argentina and 9 more
- Volunteers
- 93 people
- Sponsor
- GlaxoSmithKline
Atrial Flutter, Atrial Fibrillation
Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter
The purpose of this study is to demonstrate the effectiveness of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm.
- Trial name
- NCT00115791
- Testing
- RSD1235
- Where
- 54 sites in United States, Argentina and 5 more
- Volunteers
- 276 people
- Sponsor
- Astellas Pharma Inc
Cardiac Surgery
QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery
This trial is designed to evaluate QPI-1002 versus placebo for the prevention of Major Adverse Kidney Events (MAKE) in subjects at high risk for acute kidney injury following cardiac surgery.
- Trial name
- NCT03510897
- Testing
- teprasiran
- Where
- 104 sites in United States, Australia and 9 more
- Volunteers
- 1,043 people
- Sponsor
- Quark Pharmaceuticals
Dry Eye Syndromes
A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye
The purpose of this study is to assess the safety and efficacy of MIM-D3 Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye.
- Trial name
- NCT01960010
- Testing
- MIM-D3 Ophthalmic Solution, Vehicle
- Where
- 5 sites in United States
- Volunteers
- 403 people
- Sponsor
- Mimetogen Pharmaceuticals USA, Inc.
Idiopathic Pulmonary Fibrosis
Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)
The primary objectives of this study are to determine the effect of simtuzumab (GS-6624) on progression-free survival (PFS) as determined by either a categorical decline in forced vital capacity (FVC) or all-cause mortality, in…
- Trial name
- RAINIER (NCT01769196)
- Testing
- Simtuzumab
- Where
- 175 sites in United States, Australia and 12 more
- Volunteers
- 544 people
- Sponsor
- Gilead Sciences
Rheumatoid Arthritis
A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis
The purpose of this study is to determine whether MM-093 is safe and effective in the treatment of RA.
- Trial name
- NCT00458146
- Testing
- MM-093
- Where
- 20 sites in United States
- Volunteers
- 100 people
- Sponsor
- Merrimack Pharmaceuticals
Healthy
Multiple Dose Study of D1971a in Healthy Volunteers
This is a randomised, double-blind, placebo-controlled multiple dose study designed to explore the safety, tolerability and PK of DS-1971a following oral administration over 14 days to healthy male and female subjects.
- Trial name
- NCT02564861
- Testing
- DS-1971a
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo
Latent Tuberculosis Infection, Tuberculosis
Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection
The aim of the trial is to assess the safety, tolerability and immunogenicity of two doses of RUTI® vaccine administered four weeks apart after one month pre-treatment with INH.
- Trial name
- NCT01136161
- Testing
- RUTI
- Where
- 3 sites in South Africa
- Volunteers
- 95 people
- Sponsor
- Archivel Farma S.L.